Isolated hyperthermic liver perfusion with high dose tumor necrosis factor alpha in pigs: An experimental study in preparation of clinical use

被引:6
|
作者
Lang, H
Thyen, A
Nadalin, S
Frerker, M
Moreno, L
Flemming, P
Martin, M
Oldhafer, KJ
Raab, R
机构
[1] Hannover Med Sch, Klin Abdominal & Transplantationschirurg, Hannover, Germany
[2] Hannover Med Sch, Inst Pathol, Hannover, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
liver perfusion; isolated; hyperthermia; tumor necrosis factor-alpha;
D O I
10.1159/000008734
中图分类号
R61 [外科手术学];
学科分类号
摘要
Isolated hyperthermic perfusion of the liver was performed for 45 min in 27 pigs via hepatic artery and portal vein at mean inflow temperatures between 40.7 and 41.2 degrees C, In two study groups B and C (n = 9 pigs each) 50 mu g recombinant human tumor necrosis factor-alpha (rhTNF alpha) per kg body weight were added to the perfusate, whereas in a control group A liver perfusion was done without rhTNF alpha, Before reperfusion the livers were washed out with Ringer's solution in all groups followed by a protein solution in group C. At 30 and 60 min after reperfusion the maximum systemic rhTNF alpha concentrations were significantly higher in group B with 68 and 61 ng/ml compared to 14.5 and 14.9 ng/ml in group C (p < 0.05). Mean systemic porcine TNF alpha concentration was significantly higher in group B (217 pg/ml) compared to group C (50 pg/ml) 30 min after reperfusion (p = 0.012). Survival was 7/9 in group A and C and only 2/9 in group B with 6/7 pigs dying due to severe cardiopulmonary failure within 12 h after operation. In surviving pigs of group A and C only mild and transient hepatotoxicity was registered, The presented study underlines the feasibility of high dose rhTNF alpha application in an isolated hyperthermic liver perfusion system. Washout of the liver with a protein solution before reperfusion reduces systemic TNF alpha levels as well as associated lethal cardiocirculatory and hepatotoxic side effects. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs - Reply
    Cornett, Wendy R.
    McCall, Linda M.
    Petersen, Rebecca P.
    Herndon, James E., II
    Tyler, Douglas S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) : 1450 - 1451
  • [22] Isolated hepatic perfusion with tumor necrosis factor α and melphalan:: Experimental studies in pigs and phase I data from humans
    de Vries, MR
    Rinkes, IHB
    van de Velde, CJH
    Wiggers, T
    Tollenaar, RAEM
    Kuppen, PJK
    Vahrmeijer, AL
    Eggermont, AMM
    ISOLATED LIVER PERFUSION FOR HEPATIC TUMORS, 1998, 147 : 107 - 119
  • [23] Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor ar and melphalan on the human fibrinolytic system
    Zwaveling, JH
    Maring, JK
    Mulder, AB
    Bom, VJJ
    vanGinkel, RJ
    Koops, HS
    Girbes, ARJ
    Hoekstra, HJ
    vanderMeer, J
    CANCER RESEARCH, 1996, 56 (17) : 3948 - 3953
  • [24] Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques - A pharmacokinetic study in pigs
    van Ijken, MGA
    de Bruijn, EA
    de Boeck, G
    ten Hagen, TLM
    van der Sijp, JRM
    Eggermont, AMM
    ANNALS OF SURGERY, 1998, 228 (06) : 763 - 770
  • [25] Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies
    Libutti, SK
    Bartlett, DL
    Fraker, DL
    Alexander, HR
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 191 (05) : 519 - 530
  • [26] Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies
    De Vries, MR
    Ten Hagen, TLM
    Marinelli, AWKS
    Eggermont, AMM
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1811 - 1823
  • [27] Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
    Alexander, HR
    Bartlett, DL
    Libutti, SK
    Fraker, DL
    Moser, T
    Rosenberg, SA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1479 - 1489
  • [28] Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program
    Manusama, ER
    Nooijen, PTGA
    Ten Hagen, TLM
    Van der Veen, AH
    De Vries, MWR
    De Wilt, JHW
    Van Ijken, MG
    Marquet, RL
    Eggermont, AMM
    SEMINARS IN SURGICAL ONCOLOGY, 1998, 14 (03): : 232 - 237
  • [29] ISOLATED LUNG PERFUSION WITH TUMOR-NECROSIS-FACTOR - A SWINE MODEL IN PREPARATION OF HUMAN TRIALS
    POGREBNIAK, HW
    WITT, CJ
    TERRILL, R
    KRANDA, K
    TRAVIS, WD
    ROSENBERG, SA
    PASS, HI
    ANNALS OF THORACIC SURGERY, 1994, 57 (06): : 1477 - 1483
  • [30] Hyperthermic isolated limb perfusion with tumor necrosis factor α, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities -: A multicenter study
    Olieman, AFT
    Liénard, D
    Eggermont, AMM
    Kroon, BBR
    Lejeune, FJ
    Hoekstra, HJ
    Koops, HS
    ARCHIVES OF SURGERY, 1999, 134 (03) : 303 - 307